Search alternatives:
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
threats decrease » greater decrease (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
threats decrease » greater decrease (Expand Search)
-
1461
-
1462
-
1463
-
1464
-
1465
-
1466
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
Published 2024Subjects: -
1467
-
1468
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1469
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1470
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1471
-
1472
-
1473
-
1474
-
1475
-
1476
-
1477
-
1478
-
1479
-
1480